These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 12779088)

  • 21. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
    Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
    Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
    Joosse SA; Brandwijk KI; Devilee P; Wesseling J; Hogervorst FB; Verhoef S; Nederlof PM
    Breast Cancer Res Treat; 2012 Apr; 132(2):379-89. PubMed ID: 20614180
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genotype in BRCA-associated breast cancers.
    Meric-Bernstam F; Gutierrez-Barrera AM; Litton J; Mellor-Crummey L; Ready K; Gonzalez-Angulo AM; Lu KH; Hortobagyi GN; Arun BK
    Breast J; 2013; 19(1):87-91. PubMed ID: 23231005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breast cancer after mantle irradiation for Hodgkin's disease: correlation of clinical, pathologic, and molecular features including loss of heterozygosity at BRCA1 and BRCA2.
    Gaffney DK; Hemmersmeier J; Holden J; Marshall J; Smith LM; Avizonis V; Tran T; Neuhausen SL
    Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):539-46. PubMed ID: 11173152
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women.
    Karp SE; Tonin PN; Bégin LR; Martinez JJ; Zhang JC; Pollak MN; Foulkes WD
    Cancer; 1997 Aug; 80(3):435-41. PubMed ID: 9241077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers.
    Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Dopazo J; Rivas C; Benítez J
    Breast Cancer Res Treat; 2005 Mar; 90(1):5-14. PubMed ID: 15770521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients.
    Kwiatkowska E; Teresiak M; Filas V; Karczewska A; Breborowicz D; Mackiewicz A
    Clin Cancer Res; 2003 Oct; 9(12):4452-9. PubMed ID: 14555518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
    Reiner AS; Lynch CF; Sisti JS; John EM; Brooks JD; Bernstein L; Knight JA; Hsu L; Concannon P; Mellemkjær L; Tischkowitz M; Haile RW; Shen R; Malone KE; Woods M; Liang X; Morrow M; Bernstein JL;
    Breast Cancer Res; 2017 Jul; 19(1):83. PubMed ID: 28724391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen, estrogen, and progesterone receptor levels in malignant and benign breast tumors: a multivariate analysis approach.
    Brentani MM; Franco EL; Oshima CT; Pacheco MM
    Int J Cancer; 1986 Nov; 38(5):637-42. PubMed ID: 3770993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.
    Lakhani SR; Van De Vijver MJ; Jacquemier J; Anderson TJ; Osin PP; McGuffog L; Easton DF
    J Clin Oncol; 2002 May; 20(9):2310-8. PubMed ID: 11981002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical Evaluation of BAP1 Expression in Breast Cancer with Known
    Çalım-Gürbüz B; Güvendir İ; Ünal B; Erdoğan-Durmuş Ş; Topal CS; Ağaoğlu NB; Doğanay HL; Kızılboğa T; Zemheri IE
    Int J Surg Pathol; 2022 Jun; 30(4):397-404. PubMed ID: 35261270
    [No Abstract]   [Full Text] [Related]  

  • 33. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.
    Musolino A; Bella MA; Bortesi B; Michiara M; Naldi N; Zanelli P; Capelletti M; Pezzuolo D; Camisa R; Savi M; Neri TM; Ardizzoni A
    Breast; 2007 Jun; 16(3):280-92. PubMed ID: 17257844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
    Vos S; Vesuna F; Raman V; van Diest PJ; van der Groep P
    Oncotarget; 2015 Oct; 6(31):32115-37. PubMed ID: 26378051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of heterozygosity of p53, BRCA1, VHL, and estrogen receptor genes in breast carcinoma: correlation with related protein products and morphologic features.
    Otis CN; Krebs PA; Albuquerque A; Quezado MM; San Juan X; Sobel ME; Merino MJ
    Int J Surg Pathol; 2002 Oct; 10(4):237-45. PubMed ID: 12490973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors.
    Johannsdottir HK; Jonsson G; Johannesdottir G; Agnarsson BA; Eerola H; Arason A; Heikkila P; Egilsson V; Olsson H; Johannsson OT; Nevanlinna H; Borg A; Barkardottir RB
    Int J Cancer; 2006 Sep; 119(5):1052-60. PubMed ID: 16570289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estrogen receptor status could modulate the genomic pattern in familial and sporadic breast cancer.
    Melchor L; Honrado E; Huang J; Alvarez S; Naylor TL; García MJ; Osorio A; Blesa D; Stratton MR; Weber BL; Cigudosa JC; Rahman N; Nathanson KL; Benítez J
    Clin Cancer Res; 2007 Dec; 13(24):7305-13. PubMed ID: 18094411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3.
    Yang RL; Mick R; Lee K; Graves HL; Nathanson KL; Domchek SM; Kelz RR; Zhang PJ; Czerniecki BJ
    J Transl Med; 2015 Oct; 13():335. PubMed ID: 26496879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas.
    Rodríguez-Pinilla SM; Sarrió D; Honrado E; Moreno-Bueno G; Hardisson D; Calero F; Benítez J; Palacios J
    J Clin Pathol; 2007 Sep; 60(9):1006-12. PubMed ID: 17105822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.